Literature DB >> 9028322

Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response.

M E Ross1, M A Caligiuri.   

Abstract

Interferon-gamma (IFN-gamma) is critical for an effective innate immune response against infection. A combination of interleukins (ILs) derived from activated T cells (IL-2) and monocytes (IL-12), or monocytes alone (IL-15 and IL-12), induces optimal production of IFN-gamma from natural killer (NK) cells. The mechanism by which human NK cells downregulate their production of IFN-gamma is unknown. Here we show that the same cytokines that induce human NK cell IFN-gamma production subsequently induce apoptosis of the NK cells. Fas, bcl-2, or bax do not appear to be involved in this process. The mechanism of cytokine-induced apoptosis of human NK cells appears to involve NK cell production of tumor necrosis factor-alpha (TNF-alpha). Neutralization of TNF-alpha or inhibition of TNF-alpha binding to the p80 TNF-alpha receptor partially inhibited apoptosis. Transforming growth factor-beta, which inhibits cytokine-induced NK cell production of IFN-gamma and TNF-alpha, also decreased cytokine-induced NK cell apoptosis. Costimulation of a CD3-CD56+ NK leukemia cell line with IL-2 and IL-12 or IL-15 and IL-12 induced apoptosis in vitro, which increased when combined with a chemotherapeutic agent. In summary, costimulation of human NK cells via the IL-2 receptor and the IL-12 receptor induces significant IFN-gamma production, followed by NK cell apoptosis and a decline in IFN-gamma production. Hence, cytokines that activate this innate immune response may also serve to limit it via apoptosis. This novel observation may have implications for the regulation of the innate immune response during infection, the toxicity of combination cytokine therapy, and the treatment of NK cell leukemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028322

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

2.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

3.  Differential cytokine expression in EBV positive peripheral T cell lymphomas.

Authors:  J W Ho; R H Liang; G Srivastava
Journal:  Mol Pathol       Date:  1999-10

4.  LNFPIII/LeX-stimulated macrophages activate natural killer cells via CD40-CD40L interaction.

Authors:  Olga Atochina; Donald Harn
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

5.  ProNGF mediates death of Natural Killer cells through activation of the p75NTR-sortilin complex.

Authors:  Mary-Louise Rogers; Sheree Bailey; Dusan Matusica; Ian Nicholson; Hakan Muyderman; Promila C Pagadala; Kenneth E Neet; Heddy Zola; Peter Macardle; Robert A Rush
Journal:  J Neuroimmunol       Date:  2010-06-14       Impact factor: 3.478

6.  TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Authors:  Alexandre Ivagnès; Meriem Messaoudene; Gautier Stoll; Bertrand Routy; Aurélie Fluckiger; Takahiro Yamazaki; Kristina Iribarren; Connie P M Duong; Laetitia Fend; Anne Caignard; Isabelle Cremer; Axel LeCesne; Julien Adam; Charles Honoré; Olivier Mir; Loïc Chaigneau; Anne Berger; Pierre Validire; Christos Christidis; Valérie Le Brun-Ly; Mark J Smyth; Xavier Mariette; Benoît L Salomon; Guido Kroemer; Sylvie Rusakiewicz; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-10-11       Impact factor: 8.110

7.  Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

Authors:  V P Khatri; T A Fehniger; R A Baiocchi; F Yu; M H Shah; D S Schiller; M Gould; R T Gazzinelli; Z P Bernstein; M A Caligiuri
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

8.  Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.

Authors:  Vladimir Jurisic; Tatjana Srdic; Gordana Konjevic; Olivera Markovic; Milica Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

9.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

10.  The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma.

Authors:  Chuanyu Wei; Wenju Wang; Wei Pang; Mingyao Meng; Lihong Jiang; Sha Xue; Yanhua Xie; Ruhong Li; Zongliu Hou
Journal:  Tumour Biol       Date:  2013-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.